ZimVie Inc. (NASDAQ:ZIMV) Shares Bought by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. grew its position in ZimVie Inc. (NASDAQ:ZIMV - Free Report) by 12.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 301,316 shares of the company's stock after buying an additional 32,551 shares during the period. D. E. Shaw & Co. Inc. owned 1.09% of ZimVie worth $4,203,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in ZIMV. SG Americas Securities LLC grew its stake in shares of ZimVie by 15.7% in the 4th quarter. SG Americas Securities LLC now owns 11,110 shares of the company's stock valued at $155,000 after buying an additional 1,508 shares during the period. EMC Capital Management grew its stake in shares of ZimVie by 47.0% in the 4th quarter. EMC Capital Management now owns 13,802 shares of the company's stock valued at $193,000 after buying an additional 4,414 shares during the period. Wells Fargo & Company MN grew its stake in shares of ZimVie by 17.8% in the 4th quarter. Wells Fargo & Company MN now owns 17,037 shares of the company's stock valued at $238,000 after buying an additional 2,569 shares during the period. Integrated Quantitative Investments LLC purchased a new stake in shares of ZimVie in the 4th quarter valued at approximately $248,000. Finally, Principal Financial Group Inc. grew its stake in shares of ZimVie by 9.8% in the 4th quarter. Principal Financial Group Inc. now owns 19,054 shares of the company's stock valued at $266,000 after buying an additional 1,702 shares during the period. Hedge funds and other institutional investors own 95.63% of the company's stock.

Wall Street Analyst Weigh In

ZIMV has been the subject of several analyst reports. B. Riley initiated coverage on shares of ZimVie in a research note on Thursday, April 10th. They issued a "buy" rating and a $16.00 price target for the company. UBS Group lowered their price objective on shares of ZimVie from $16.00 to $10.00 and set a "neutral" rating for the company in a research report on Thursday, May 15th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of ZimVie in a research report on Wednesday, April 9th.

ZimVie Trading Down 0.8%

Shares of NASDAQ:ZIMV traded down $0.07 during mid-day trading on Friday, reaching $8.28. 180,965 shares of the company were exchanged, compared to its average volume of 211,662. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.94 and a quick ratio of 1.38. The firm has a market cap of $230.57 million, a price-to-earnings ratio of -0.63 and a beta of 2.16. The firm's 50-day simple moving average is $9.58 and its 200 day simple moving average is $12.29. ZimVie Inc. has a 1 year low of $8.15 and a 1 year high of $22.40.

ZimVie (NASDAQ:ZIMV - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.27 earnings per share for the quarter, topping analysts' consensus estimates of $0.21 by $0.06. The firm had revenue of $112.00 million during the quarter, compared to analysts' expectations of $113.10 million. ZimVie had a negative net margin of 77.31% and a positive return on equity of 2.90%. Equities research analysts forecast that ZimVie Inc. will post 0.6 EPS for the current year.

About ZimVie

ZimVie Inc, together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment.